CannaBiz Innovation Hub 2019: innovation and scale with cannabis – Health Europa

© iStock/Bim

Leading organisations in the cannabis industry will be discussing cannabis products, the supply chain, quality control, marketing, distribution and more at Cannabis Innovation Hub 2019.

On December 4 and 5 2019, the CannaBiz Innovation Hub will bring together senior executives from leading cannabis consumer and devices product categories, as well as representatives from consumer-packaged goods and pharmaceutical organisations.

The event is centred around uncovering solutions that enable mainstream product innovation and scale with cannabis as an ingredient.

Health Europa is delighted to partner with Cannabis Innovation Hub 2019 – the event will take place in London on 4-5 December 2019. Book your tickets here.

Innovative and leading solutions

Joined by innovative and leading solutions providers the product innovators will identify:

  • Opportunities to scale product innovation by identifying key consumer trends and the latest regulatory updates;
  • how to build brands and products that consumers love by hearing insights from legacy CPGs organisations on developing products with ‘problematic’ ingredients;
  • opportunities and risks in key CPG categories: food & beverage as well as cosmetics;
  • where are the opportunities and risks for a cannabis-based medicine innovation in 2020;
  • how to overcome the prescription challenge in Europe;
  • what are the latest findings and developments from research studies uncovering new opportunities for cannabis ingredients and API’s; and
  • identifying the QA/QC framework necessary for delivering quality products on a global scale

Product innovation and R&D is essential and absolutely crucial to maximising future opportunities.

Featuring a global speaker faculty, this event will focus on the European market and will address the innovation bottlenecks across the entire cannabis value chain.

Cannabiz Innovation Hub offers a unique platform to debate best practices that are imperative to enabling scale, efficiency and industrialisation of products and medicines in the emerging legal cannabis markets.

Alongside the cannabis industry leaders will also feature the experience of large CPG’s and pharma organisations in enabling scale of innovative products with ‘problematic’ ingredients.

The cannabis market is moving extremely fast, in order to embrace hyper-growth opportunities, execute breakthrough industry-firsts and sustain market leadership – you need to be armed with contacts, knowledge and the enterprise vision.

We are edging ever closer to products containing cannabis ingredients becoming mainstream. This entails large scale product innovation, supply chain, quality control, marketing, distribution and so on.

The success of the wellness cannabis product sector is linked with medical cannabis. The first will continue to thrive as more research is carried out in the medical field and as more patients benefit from prescriptions for medicinal cannabis.

On December 4 and 5 2019 in London, senior executives from leading product innovators, cannabis consumers, medical and devices product categories, as well as legacy CPG and pharmaceutical organisations and medical professionals, will meet to uncover how to unleash scale – cannabis in healthcare and consumer products

The goal of this event is to debate solutions to the innovation and scale challenges with one day dedicated to the health and wellness consumer and one day dedicated to the patient.

On December 4 topics will range from the Novel Foods Act to marketing and branding strategy, bioavailability, sector opportunities and so much more. Creating products that consumers love on a global scale must be underpinned by a rigorous quality control and quality assurance framework.  John Carter, Vice President, Quality and Food Safety, EDP WBU previously with Danone will share his views on how to overcome the biggest challenges and implement such framework.

On this day other speakers include:

  • Mark Reinders, CEO, HempFlax Group Bv;
  • Penny Green, President & CEO, The Yield Growth Corp;
  • Ingeborg Gasser-Kriss, former VP Global Innovation, Mondelez International;
  • Dr Vladas Snieckus, Chief Operating Officer & Chief Medical Officer, Hempfy;
  • Gabriel Micallef, Regulatory Submission Manager, Janssen Inc;
  • Ben King, Associate, Bird & Bird; and
  • June Nicholson, EVP Partnerships & Government Affairs, Hill Street Beverage Company.

Whilst CBD is currently the most discussed active pharmaceutical ingredient (API) in the wider industry, the Cannabis Innovation Hub is designed to provide a strategic framework that can be applied effectively with any other active ingredient in the cannabis plant.

On December 4 the organisers have scheduled a European themed drinks reception – this means great nibbles, different national drinks and networking hubs around regions. Is designed to ensure the delegates have an amazing experience and walk away with actionable insights and real opportunities for business development.

During December 5 the day will be filled with debates and panel discussions seeking to identify solutions for improving access to medicinal cannabis.  Of course, clinical trials hold much of the answer but what is the solution right now, that will improve access for patients over the coming five years? Running clinical studies with cannabis is extremely challenging.  Achieving consistency with the cannabis plant is one of the main reasons but synthetic cannabinoid producers are here to fill the gap.

Is this the right strategy?

On December 5 you will have the opportunity to evaluate the journey of two exciting clinical studies with plant-based API’s and also evaluate the role of synthetically produced cannabinoids.

An engaging, truly unique and refreshing speaker faculty includes:

  • Xenia Von Maltzan, Principal Consultant, ProPharma Group Germany;
  • Dr Nicolas Van Elsué, Centre Médical Rollingergrund (Luxemburg);
  • Hannah Deacon, Mother of Alfie Dingley;
  • Professor Mike Barnes, Consultant Neurologist, UK NHS;
  • Dr Rina Carlini, Vice President, Research & Innovation, Rapid Dose Therapeutics Corp;
  • Dr. Daniela Eigenmann Pharmacist, Bahnhof Apotheke Langnau AG;
  • Rachel Dorsey-Campbell, Senior Lead Pharmacist Neurosciences, Imperial NHS Trust; and
  • Felipe Velasquez, CEO & Co-Founder, FCM Global.

With over 200 attendees this conference is not a trade show but is designed to be inclusive and valuable from a networking and learning perspective. This is the best opportunity to evaluate the potential for the cannabis ingredients in terms of business and product innovation – is about what the cannabis ingredients can empower.

The team at the CannaBiz Innovation Hub are committed to providing a truly independent platform, a genuine opportunity for debate and networking for both the existing cannabis brand owners, cannabis industry experts and brand owners who are planning on integrating cannabis ingredients in their existing portfolio.

For a full agenda and registration details please see or email

Mihaela Biti
Head of Research & Development
Cannabis Innovation Hub
+00 4420 8068 6664

Dodaj komentarz